Dexcom Inc (NASDAQ: DXCM) kicked off on Friday, up 1.11% from the previous trading day, before settling in for the closing price of $84.86. Over the past 52 weeks, DXCM has traded in a range of $57.52-$127.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.27%. While this was happening, its average annual earnings per share was recorded 23.52%. With a float of $386.42 million, this company’s outstanding shares have now reached $392.10 million.
Let’s determine the extent of company efficiency that accounts for 10300 employees. In terms of profitability, gross margin is 59.39%, operating margin of 15.25%, and the pretax margin is 17.62%.
Dexcom Inc (DXCM) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Dexcom Inc is 1.44%, while institutional ownership is 93.67%. The most recent insider transaction that took place on May 27 ’25, was worth 526,318. In this transaction EVP, Chief HR Officer of this company sold 6,184 shares at a rate of $85.11, taking the stock ownership to the 109,621 shares. Before that another transaction happened on May 23 ’25, when Company’s EVP, Chief Legal Officer sold 10,000 for $84.28, making the entire transaction worth $842,849. This insider now owns 95,602 shares in total.
Dexcom Inc (DXCM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.87% during the next five years compared to 39.06% growth over the previous five years of trading.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Take a look at Dexcom Inc’s (DXCM) current performance indicators. Last quarter, stock had a quick ratio of 1.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.11. Likewise, its price to free cash flow for the trailing twelve months is 58.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.33, a number that is poised to hit 0.45 in the next quarter and is forecasted to reach 2.54 in one year’s time.
Technical Analysis of Dexcom Inc (DXCM)
Looking closely at Dexcom Inc (NASDAQ: DXCM), its last 5-days average volume was 3.09 million, which is a drop from its year-to-date volume of 4.1 million. As of the previous 9 days, the stock’s Stochastic %D was 57.39%. Additionally, its Average True Range was 2.48.
During the past 100 days, Dexcom Inc’s (DXCM) raw stochastic average was set at 79.15%, which indicates a significant increase from 55.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.58% in the past 14 days, which was lower than the 47.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $75.00, while its 200-day Moving Average is $76.03. However, in the short run, Dexcom Inc’s stock first resistance to watch stands at $86.78. Second resistance stands at $87.77. The third major resistance level sits at $88.73. If the price goes on to break the first support level at $84.83, it is likely to go to the next support level at $83.87. Should the price break the second support level, the third support level stands at $82.88.
Dexcom Inc (NASDAQ: DXCM) Key Stats
The company with the Market Capitalisation of 33.64 billion has total of 392,107K Shares Outstanding. Its annual sales at the moment are 4,033 M in contrast with the sum of 576,200 K annual income. Company’s last quarter sales were recorded 1,036 M and last quarter income was 105,400 K.
